Liliya Rostomyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Liliya Rostomyan has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Albert Beckers
Department of Endocrinology Centre Hospitalier Universitaire de Liège, University of Liège Liège Belgium
13 shared publications - Adrian F. Daly
Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, 4000 Liège, Belgium
11 shared publications - Anne Barlier
Aix Marseille Univ, APHM, INSERM, MMG, MarMaRa institute, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, BIOGENOPOLE, Marseille, France
4 shared publications Emilie Castermans
4 shared publications- Giampaolo Trivellin
Department of Biomedical Sciences, Humanitas University
4 shared publications - Marie-Lise Jaffrain-Rea
Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
4 shared publications
Latest Publications
- Open Access
High prevalence of deleterious germline variants in cancer risk genes among subjects with young-onset, sporadic pituitary macroadenomas
Introduction: Pituitary adenomas/pituitary neuroendocrine tumors (PitNETs) are common intracranial tumors, clinically affecting 1:1000 individuals and most cases remain genetically unexplained. Emerging research has highlighted the major contribution of germline pathogenic variants to tumorigenesis across many tissue types in young subjects . We investigated whether young-onset (AIP, MEN1, CDKN1B ) or duplications ( GPR101 ). Whole-exome sequencing (WES) was performed on germline DNA. Bioinformatics analysis including variant calling (for small variants and CNVs), annotation and variant prioritization were performed, using secondary analysis pipelines for WES data and AION predictor platform for tertiary analysis. Variants in established cancer-risk genes were prioritized. Results: P/LP germline variants in cancer-risk genes were identified in 14.6% of subjects on ClinVar/ACMG criteria. This rose to 31.3% of subject with deleterious variants when additional in silico and AION predictor criteria were used. Genes included: BAP1, BRCA1, BUB1, ELAC2, FLCN, MCPH1, MSR1, MUTYH, PDE11A, POLE, POLG, PMS2, RAD51C, RECQL4, SDHA, SDHD, SEC23B, TMEM127, WRN . Conclusions: Our findings expand the spectrum of genes potentially associated with young-onset pituitary macroadenomas. The identification of a high rate of deleterious germline variants in cancer-risk genes in pituitary adenomas/PitNETs echoes similar findings in young patients across a wide range of tumors. These results may have relevance for genetic counseling and potentially could expand targeted management strategies in young patients with large pituitary tumors.
Open AccessHigh prevalence of deleterious germline variants in cancer risk genes among subjects with young-onset, sporadic pituitary macroadenomas
Introduction: Pituitary adenomas/pituitary neuroendocrine tumors (PitNETs) are common intracranial tumors, clinically affecting 1:1000 individuals and most cases remain genetically unexplained. Emerging research has highlighted the major contribution of germline pathogenic variants to tumorigenesis across many tissue types in young subjects . We investigated whether young-onset (AIP, MEN1, CDKN1B ) or duplications ( GPR101 ). Whole-exome sequencing (WES) was performed on germline DNA. Bioinformatics analysis including variant calling (for small variants and CNVs), annotation and variant prioritization were performed, using secondary analysis pipelines for WES data and AION predictor platform for tertiary analysis. Variants in established cancer-risk genes were prioritized. Results: P/LP germline variants in cancer-risk genes were identified in 14.6% of subjects on ClinVar/ACMG criteria. This rose to 31.3% of subject with deleterious variants when additional in silico and AION predictor criteria were used. Genes included: BAP1, BRCA1, BUB1, ELAC2, FLCN, MCPH1, MSR1, MUTYH, PDE11A, POLE, POLG, PMS2, RAD51C, RECQL4, SDHA, SDHD, SEC23B, TMEM127, WRN . Conclusions: Our findings expand the spectrum of genes potentially associated with young-onset pituitary macroadenomas. The identification of a high rate of deleterious germline variants in cancer-risk genes in pituitary adenomas/PitNETs echoes similar findings in young patients across a wide range of tumors. These results may have relevance for genetic counseling and potentially could expand targeted management strategies in young patients with large pituitary tumors.
- Open Access
- 26 March 2021
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 17 (1) , 11-19
Сучасні погляди на генетичну детермінованість СТГ-секретуючих аденом гіпофіза (огляд літератури та власні дослідження)
Актуальність. В роботі наведений огляд сучасних даних літератури щодо генетичної складової в етіології та патогенезі гормонально активної аденоми гіпофіза, що секретує соматотропний гормон (СТГ) і клінічними проявами якої є синдром акромегалії та/або гігантизму— синдром множинної ендокринної неоплазії 1, синдром Мак-К’юна— Олбрайта, комплекс Карні, акрогігантизм (Х-зчеплений), сімейні ізольовані аденоми гіпофіза (FIPA). Матеріали та методи. Для виявлення мутацій в гені AIP та з метою верифікації FIPA були обстежені 26 хворих української популяції (19 жінок та 7 чоловіків), в яких акромегалія була діагностована в підлітковому або молодому віці, і проведений генетичний аналіз. Для визначення генетичної детермінованості щодо розвитку СТГ-секретуючої аденоми гіпофіза та диференціальної діагностики синдромів FIPA та MEN1 методом секвенування (MLPA— Ligation-dependent Probe Amplification) було проведене дослідження генів (MLPA, P244-C1) за участю екзонів 1–6 MEN1, (MLPA, P017-D1) AIP. Результати. Серед обстежених тільки у двох осіб були визначені мутації гена AIP. В одного хворого генетичний скринінг на мутацію гена MEN1 був негативним, і жодних клінічних симптомів, що свідчать про синдром Мак-К’юна— Олбрайта, не було виявлено. Варіант гетерозиготного місенсу c.714C>G (p.Cys238Trp) виявлений у гені AIP. Цей аналіз гена AIP сумісний з генетичною схильністю до аденом гіпофіза. У нащадків даного пацієнта 50% шансів успадкувати цей варіант. У іншої хворої з діагнозом «синдром множинної ендокринної неоплазії типу1 (синдром Вермера): інсулінома, аденоми прищитоподібних залоз (2), первинний гіперпаратиреоз» встановлений варіант гетерозиготного місенсу c.134A>G (p.Glu45Gly), що був виявлений у гені MEN1. Варіант c.l34A>G (p.Glu45Gly), клас 4, ймовірно, є патогенним. Поширеність цього варіанта в загальній популяції невідома, тому він є дуже рідкісним. Висновки. Проведення генетичного аналізу є доцільним у хворих дитячого та молодого віку або в осіб, у яких СТГ-секретуюча макро-/гігантська аденома гіпофіза була діагностована в молодому віці (до 35 років), незалежно від сімейної обтяженості щодо аденом гіпофіза. У хворих з обтяженою спадковістю генетичний аналіз доцільно проводити у будь-якому разі для виявлення FIPA та прогнозування подальшого перебігу захворювання та ефективності лікування аналогами соматостатину.
- 26 March 2021
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 17 (1) , 11-19
Open AccessСучасні погляди на генетичну детермінованість СТГ-секретуючих аденом гіпофіза (огляд літератури та власні дослідження)
Актуальність. В роботі наведений огляд сучасних даних літератури щодо генетичної складової в етіології та патогенезі гормонально активної аденоми гіпофіза, що секретує соматотропний гормон (СТГ) і клінічними проявами якої є синдром акромегалії та/або гігантизму— синдром множинної ендокринної неоплазії 1, синдром Мак-К’юна— Олбрайта, комплекс Карні, акрогігантизм (Х-зчеплений), сімейні ізольовані аденоми гіпофіза (FIPA). Матеріали та методи. Для виявлення мутацій в гені AIP та з метою верифікації FIPA були обстежені 26 хворих української популяції (19 жінок та 7 чоловіків), в яких акромегалія була діагностована в підлітковому або молодому віці, і проведений генетичний аналіз. Для визначення генетичної детермінованості щодо розвитку СТГ-секретуючої аденоми гіпофіза та диференціальної діагностики синдромів FIPA та MEN1 методом секвенування (MLPA— Ligation-dependent Probe Amplification) було проведене дослідження генів (MLPA, P244-C1) за участю екзонів 1–6 MEN1, (MLPA, P017-D1) AIP. Результати. Серед обстежених тільки у двох осіб були визначені мутації гена AIP. В одного хворого генетичний скринінг на мутацію гена MEN1 був негативним, і жодних клінічних симптомів, що свідчать про синдром Мак-К’юна— Олбрайта, не було виявлено. Варіант гетерозиготного місенсу c.714C>G (p.Cys238Trp) виявлений у гені AIP. Цей аналіз гена AIP сумісний з генетичною схильністю до аденом гіпофіза. У нащадків даного пацієнта 50% шансів успадкувати цей варіант. У іншої хворої з діагнозом «синдром множинної ендокринної неоплазії типу1 (синдром Вермера): інсулінома, аденоми прищитоподібних залоз (2), первинний гіперпаратиреоз» встановлений варіант гетерозиготного місенсу c.134A>G (p.Glu45Gly), що був виявлений у гені MEN1. Варіант c.l34A>G (p.Glu45Gly), клас 4, ймовірно, є патогенним. Поширеність цього варіанта в загальній популяції невідома, тому він є дуже рідкісним. Висновки. Проведення генетичного аналізу є доцільним у хворих дитячого та молодого віку або в осіб, у яких СТГ-секретуюча макро-/гігантська аденома гіпофіза була діагностована в молодому віці (до 35 років), незалежно від сімейної обтяженості щодо аденом гіпофіза. У хворих з обтяженою спадковістю генетичний аналіз доцільно проводити у будь-якому разі для виявлення FIPA та прогнозування подальшого перебігу захворювання та ефективності лікування аналогами соматостатину.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Combined treatment with octreotide LAR and pegvisomant in patients with gigantism - acromegaly: clinical evaluation and genetic screening
Pituitary gigantism is a rare condition caused by growth hormone secreting lesions, where treatment is usually challenging, especially in cases with genetic predisposition. Aim: We studied a gigantism cohort from Venezuela for genetic defects and their response to treatment. Subjects: 160 somatotropinoma patients were evaluated at the University hospital (from 1985–2015); eight (6M) were diagnosed with acrogigantism and underwent genetic analysis including aCGH for Xq26.3 duplications. Results: All patients had accelerated growth rates/tall stature at first evaluation. The mean age at diagnosis was 18.7 years (range 12–28). Among other frequent signs/symptoms at presentation were acral enlargement (7/8) and headache (5/8). All presented with growth hormone-secreting macroadenomas (all except one were invasive) with prolactin co-secretion seen in 4 cases. Six cases received primary medical treatment with the long-acting somatostatin analogue (SSA) octreotide LAR 20 mg/28 days for 6–12 months resulting in tumor control in 64%, in 2 patients SSA treatment was administrated after unsuccessful surgery (radiotherapy was also used in one case). Cabergoline was added in those with elevated prolactin levels. None of the patients had normalization of IGF-1 levels with SSA. Pegvisomant (20 mg daily) was added. And this combination resulted in a decrease of IGF-1 levels to normal ranges while tumor volume was stable in all patients. Regression of clinical symptoms was seen after 1–4 months of treatment including a decrease in growth velocity. Three novel AIP mutations were identified and none of the patients had Xq26.3 microduplications. Clinical characteristics at baseline and treatment responses were not different in patients with AIP mutations compared with AIP negatives. Conclusions: Patients with gigantism have large and aggressive GH secreting pituitary lesions difficult to control with conventional treatment options. Prolactin co-secresion is frequent. Combined therapy (long-lasting SSA and pegvisomant) as primary treatment or after pituitary surgery and radiotherapy can permit the normalization of IGF-1 levels and achieve clinical improvement in these difficult to manage patients.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Combined treatment with octreotide LAR and pegvisomant in patients with gigantism - acromegaly: clinical evaluation and genetic screening
Pituitary gigantism is a rare condition caused by growth hormone secreting lesions, where treatment is usually challenging, especially in cases with genetic predisposition. Aim: We studied a gigantism cohort from Venezuela for genetic defects and their response to treatment. Subjects: 160 somatotropinoma patients were evaluated at the University hospital (from 1985–2015); eight (6M) were diagnosed with acrogigantism and underwent genetic analysis including aCGH for Xq26.3 duplications. Results: All patients had accelerated growth rates/tall stature at first evaluation. The mean age at diagnosis was 18.7 years (range 12–28). Among other frequent signs/symptoms at presentation were acral enlargement (7/8) and headache (5/8). All presented with growth hormone-secreting macroadenomas (all except one were invasive) with prolactin co-secretion seen in 4 cases. Six cases received primary medical treatment with the long-acting somatostatin analogue (SSA) octreotide LAR 20 mg/28 days for 6–12 months resulting in tumor control in 64%, in 2 patients SSA treatment was administrated after unsuccessful surgery (radiotherapy was also used in one case). Cabergoline was added in those with elevated prolactin levels. None of the patients had normalization of IGF-1 levels with SSA. Pegvisomant (20 mg daily) was added. And this combination resulted in a decrease of IGF-1 levels to normal ranges while tumor volume was stable in all patients. Regression of clinical symptoms was seen after 1–4 months of treatment including a decrease in growth velocity. Three novel AIP mutations were identified and none of the patients had Xq26.3 microduplications. Clinical characteristics at baseline and treatment responses were not different in patients with AIP mutations compared with AIP negatives. Conclusions: Patients with gigantism have large and aggressive GH secreting pituitary lesions difficult to control with conventional treatment options. Prolactin co-secresion is frequent. Combined therapy (long-lasting SSA and pegvisomant) as primary treatment or after pituitary surgery and radiotherapy can permit the normalization of IGF-1 levels and achieve clinical improvement in these difficult to manage patients.
- 1 February 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (1) , 60
Erratum to “Pituitary gigantism: Causes and clinical characteristics” [Ann. Endocrinol. (Paris) 76 (2015) 643–649]
- 1 February 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (1) , 60
Erratum to “Pituitary gigantism: Causes and clinical characteristics” [Ann. Endocrinol. (Paris) 76 (2015) 643–649]
- 1 December 2015
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 76 (6) , 643-649
Pituitary gigantism: Causes and clinical characteristics
- 1 December 2015
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 76 (6) , 643-649
Pituitary gigantism: Causes and clinical characteristics
- 17 July 2015
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 22 (5) , 745-757
Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients
Despite being a classical growth disorder, pituitary gigantism has not been studied previously in a standardized way. We performed a retrospective, multicenter, international study to characterize a large series of pituitary gigantism patients. We included 208 patients (163 males; 78.4%) with growth hormone excess and a current/previous abnormal growth velocity for age or final height >2s.d.above country normal means. The median onset of rapid growth was 13 years and occurred significantly earlier in females than in males; pituitary adenomas were diagnosed earlier in females than males (15.8 vs 21.5 years respectively). Adenomas were ≥10 mm (i.e., macroadenomas) in 84%, of which extrasellar extension occurred in 77% and invasion in 54%. GH/IGF1 control was achieved in 39% during long-term follow-up. Final height was greater in younger onset patients, with larger tumors and higher GH levels. Later disease control was associated with a greater difference from mid-parental height (r=0.23,P=0.02).AIPmutations occurred in 29%; microduplication at Xq26.3 – X-linked acrogigantism (X-LAG) – occurred in two familial isolated pituitary adenoma kindreds and in ten sporadic patients. Tumor size was not different in X-LAG,AIPmutated and genetically negative patient groups.AIP-mutated and X-LAG patients were significantly younger at onset and diagnosis, but disease control was worse in genetically negative cases. Pituitary gigantism patients are characterized by male predominance and large tumors that are difficult to control. Treatment delay increases final height and symptom burden.AIPmutations and X-LAG explain many cases, but no genetic etiology is seen in >50% of cases.
- 17 July 2015
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 22 (5) , 745-757
Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients
Despite being a classical growth disorder, pituitary gigantism has not been studied previously in a standardized way. We performed a retrospective, multicenter, international study to characterize a large series of pituitary gigantism patients. We included 208 patients (163 males; 78.4%) with growth hormone excess and a current/previous abnormal growth velocity for age or final height >2s.d.above country normal means. The median onset of rapid growth was 13 years and occurred significantly earlier in females than in males; pituitary adenomas were diagnosed earlier in females than males (15.8 vs 21.5 years respectively). Adenomas were ≥10 mm (i.e., macroadenomas) in 84%, of which extrasellar extension occurred in 77% and invasion in 54%. GH/IGF1 control was achieved in 39% during long-term follow-up. Final height was greater in younger onset patients, with larger tumors and higher GH levels. Later disease control was associated with a greater difference from mid-parental height (r=0.23,P=0.02).AIPmutations occurred in 29%; microduplication at Xq26.3 – X-linked acrogigantism (X-LAG) – occurred in two familial isolated pituitary adenoma kindreds and in ten sporadic patients. Tumor size was not different in X-LAG,AIPmutated and genetically negative patient groups.AIP-mutated and X-LAG patients were significantly younger at onset and diagnosis, but disease control was worse in genetically negative cases. Pituitary gigantism patients are characterized by male predominance and large tumors that are difficult to control. Treatment delay increases final height and symptom burden.AIPmutations and X-LAG explain many cases, but no genetic etiology is seen in >50% of cases.
- Open Access
- 1 June 2015
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 22 (3) , 353-367
X-linked acrogigantism syndrome: clinical profile and therapeutic responses
X-linked acrogigantism (X-LAG) is a new syndrome of pituitary gigantism, caused by microduplications on chromosome Xq26.3, encompassing the geneGPR101, which is highly upregulated in pituitary tumors. We conducted this study to explore the clinical, radiological, and hormonal phenotype and responses to therapy in patients with X-LAG syndrome. The study included 18 patients (13 sporadic) with X-LAG and microduplication of chromosome Xq26.3. All sporadic cases had unique duplications and the inheritance pattern in two families was dominant, with all Xq26.3 duplication carriers being affected. Patients began to grow rapidly as early as 2–3 months of age (median 12 months). At diagnosis (median delay 27 months), patients had a median height and weight standard deviation scores (SDS) of >+3.9 SDS. Apart from the increased overall body size, the children had acromegalic symptoms including acral enlargement and facial coarsening. More than a third of cases had increased appetite. Patients had marked hypersecretion of GH/IGF1 and usually prolactin, due to a pituitary macroadenoma or hyperplasia. Primary neurosurgical control was achieved with extensive anterior pituitary resection, but postoperative hypopituitarism was frequent. Control with somatostatin analogs was not readily achieved despite moderate to high levels of expression of somatostatin receptor subtype-2 in tumor tissue. Postoperative use of adjuvant pegvisomant resulted in control of IGF1 in all five cases where it was employed. X-LAG is a new infant-onset gigantism syndrome that has a severe clinical phenotype leading to challenging disease management.
- 1 June 2015
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 22 (3) , 353-367
Open AccessX-linked acrogigantism syndrome: clinical profile and therapeutic responses
X-linked acrogigantism (X-LAG) is a new syndrome of pituitary gigantism, caused by microduplications on chromosome Xq26.3, encompassing the geneGPR101, which is highly upregulated in pituitary tumors. We conducted this study to explore the clinical, radiological, and hormonal phenotype and responses to therapy in patients with X-LAG syndrome. The study included 18 patients (13 sporadic) with X-LAG and microduplication of chromosome Xq26.3. All sporadic cases had unique duplications and the inheritance pattern in two families was dominant, with all Xq26.3 duplication carriers being affected. Patients began to grow rapidly as early as 2–3 months of age (median 12 months). At diagnosis (median delay 27 months), patients had a median height and weight standard deviation scores (SDS) of >+3.9 SDS. Apart from the increased overall body size, the children had acromegalic symptoms including acral enlargement and facial coarsening. More than a third of cases had increased appetite. Patients had marked hypersecretion of GH/IGF1 and usually prolactin, due to a pituitary macroadenoma or hyperplasia. Primary neurosurgical control was achieved with extensive anterior pituitary resection, but postoperative hypopituitarism was frequent. Control with somatostatin analogs was not readily achieved despite moderate to high levels of expression of somatostatin receptor subtype-2 in tumor tissue. Postoperative use of adjuvant pegvisomant resulted in control of IGF1 in all five cases where it was employed. X-LAG is a new infant-onset gigantism syndrome that has a severe clinical phenotype leading to challenging disease management.
- 7 April 2015
- Published by Springer Nature in Neuroradiology
- Vol. 57 (7) , 679-684
Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference
Clinical presentations of prolactinomas are quite different between genders. In comparison with women’s prolactinoma, those in men showed predominance of large tumors with high prolactin (PRL) levels. This preponderance could be attributed to a greater proliferative potential of the tumors. Differences in magnetic resonance imaging (MRI) signal at diagnosis have not been yet clearly evaluated. We conduct a retrospective study comparing MRI signal intensity (SI) on T2-weighted images (T2-WI) between 41 men and 41 women to investigate whether or not men prolactinoma present specific features. In addition to the size of the adenoma and PRL levels (P < 0001), prolactinomas in men also exhibit differences from those in women in signal on T2-WI on MRI (P < 0001). Women’s prolactinomas are mostly of high SI on T2-WI while men’s prolactinomas exhibit a more heterogeneous pattern of SI on T2-WI. Prolactinomas presenting with low SI on T2-WI are almost exclusively encountered in men. Presence of T2-WI hypointensities in pituitary adenoma can be predictive of a different subtype of prolactinoma almost encountered in men and possibly translate the presence of spherical amyloid deposits, in agreement with the literature.
- 7 April 2015
- Published by Springer Nature in Neuroradiology
- Vol. 57 (7) , 679-684
Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference
Clinical presentations of prolactinomas are quite different between genders. In comparison with women’s prolactinoma, those in men showed predominance of large tumors with high prolactin (PRL) levels. This preponderance could be attributed to a greater proliferative potential of the tumors. Differences in magnetic resonance imaging (MRI) signal at diagnosis have not been yet clearly evaluated. We conduct a retrospective study comparing MRI signal intensity (SI) on T2-weighted images (T2-WI) between 41 men and 41 women to investigate whether or not men prolactinoma present specific features. In addition to the size of the adenoma and PRL levels (P < 0001), prolactinomas in men also exhibit differences from those in women in signal on T2-WI on MRI (P < 0001). Women’s prolactinomas are mostly of high SI on T2-WI while men’s prolactinomas exhibit a more heterogeneous pattern of SI on T2-WI. Prolactinomas presenting with low SI on T2-WI are almost exclusively encountered in men. Presence of T2-WI hypointensities in pituitary adenoma can be predictive of a different subtype of prolactinoma almost encountered in men and possibly translate the presence of spherical amyloid deposits, in agreement with the literature.
- Top Cited Papers
- 18 December 2014
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (25) , 2363-2374
Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation
Increased secretion of growth hormone leads to gigantism in children and acromegaly in adults; the genetic causes of gigantism and acromegaly are poorly understood. We performed clinical and genetic studies of samples obtained from 43 patients with gigantism and then sequenced an implicated gene in samples from 248 patients with acromegaly. We observed microduplication on chromosome Xq26.3 in samples from 13 patients with gigantism; of these samples, 4 were obtained from members of two unrelated kindreds, and 9 were from patients with sporadic cases. All the patients had disease onset during early childhood. Of the patients with gigantism who did not carry an Xq26.3 microduplication, none presented before the age of 5 years. Genomic characterization of the Xq26.3 region suggests that the microduplications are generated during chromosome replication and that they contain four protein-coding genes. Only one of these genes, GPR101, which encodes a G-protein–coupled receptor, was overexpressed in patients' pituitary lesions. We identified a recurrent GPR101 mutation (p.E308D) in 11 of 248 patients with acromegaly, with the mutation found mostly in tumors. When the mutation was transfected into rat GH3 cells, it led to increased release of growth hormone and proliferation of growth hormone–producing cells. We describe a pediatric disorder (which we have termed X-linked acrogigantism [X-LAG]) that is caused by an Xq26.3 genomic duplication and is characterized by early-onset gigantism resulting from an excess of growth hormone. Duplication of GPR101 probably causes X-LAG. We also found a recurrent mutation in GPR101 in some adults with acromegaly. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others.)
- 18 December 2014
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (25) , 2363-2374
Top Cited PapersGigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation
Increased secretion of growth hormone leads to gigantism in children and acromegaly in adults; the genetic causes of gigantism and acromegaly are poorly understood. We performed clinical and genetic studies of samples obtained from 43 patients with gigantism and then sequenced an implicated gene in samples from 248 patients with acromegaly. We observed microduplication on chromosome Xq26.3 in samples from 13 patients with gigantism; of these samples, 4 were obtained from members of two unrelated kindreds, and 9 were from patients with sporadic cases. All the patients had disease onset during early childhood. Of the patients with gigantism who did not carry an Xq26.3 microduplication, none presented before the age of 5 years. Genomic characterization of the Xq26.3 region suggests that the microduplications are generated during chromosome replication and that they contain four protein-coding genes. Only one of these genes, GPR101, which encodes a G-protein–coupled receptor, was overexpressed in patients' pituitary lesions. We identified a recurrent GPR101 mutation (p.E308D) in 11 of 248 patients with acromegaly, with the mutation found mostly in tumors. When the mutation was transfected into rat GH3 cells, it led to increased release of growth hormone and proliferation of growth hormone–producing cells. We describe a pediatric disorder (which we have termed X-linked acrogigantism [X-LAG]) that is caused by an Xq26.3 genomic duplication and is characterized by early-onset gigantism resulting from an excess of growth hormone. Duplication of GPR101 probably causes X-LAG. We also found a recurrent mutation in GPR101 in some adults with acromegaly. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others.)
- 1 October 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (10) , E2029-E2038
McCune-Albright Syndrome: A Detailed Pathological and Genetic Analysis of Disease Effects in an Adult Patient
McCune Albright syndrome (MAS) is a clinical association of endocrine and nonendocrine anomalies caused by postzygotic mutation of the GNAS1 gene, leading to somatic activation of the stimulatory α-subunit of G protein (Gsα). Important advances have been made recently in describing pathological characteristics of many MAS-affected tissues, particularly pituitary, testicular, and adrenal disease. Other rarer disease related features are emerging. The objective of the investigation was to study the pathological and genetic findings of MAS on a tissue-by-tissue basis in classically and nonclassically affected tissues. This was a comprehensive autopsy and genetic analysis. The study was conducted at a tertiary referral university hospital. An adult male patient with MAS and severe disease burden including gigantism was the subject of the study. Interventions included clinical, hormonal, and radiographic studies and gross and microscopic pathology analyses, conventional PCR, and droplet digital PCR analyses of affected and nonaffected tissues. Pathological findings and the presence of GNAS1 mutations were measured. The patient was diagnosed with MAS syndrome at 6 years of age based on the association of café-au-lait spots and radiological signs of polyostotic fibrous dysplasia. Gigantism developed and hyperprolactinemia, hypogonadotropic hypogonadism, and hyperparathyroidism were diagnosed throughout the adult period. The patient died at the age of 39 years from a pulmonary embolism. A detailed study revealed mosaiscism for the p.R201C GNAS1 mutation distributed across many endocrine and nonendocrine tissues. These genetically implicated tissues included rare or previously undescribed disease associations including primary hyperparathyroidism and hyperplasia of the thymus and endocrine pancreas. This comprehensive pathological study of a single patient highlights the complex clinical profile of MAS and illustrates important advances in understanding the characteristics of somatic GNAS1-related pathology across a wide range of affected organs.
- 1 October 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (10) , E2029-E2038
McCune-Albright Syndrome: A Detailed Pathological and Genetic Analysis of Disease Effects in an Adult Patient
McCune Albright syndrome (MAS) is a clinical association of endocrine and nonendocrine anomalies caused by postzygotic mutation of the GNAS1 gene, leading to somatic activation of the stimulatory α-subunit of G protein (Gsα). Important advances have been made recently in describing pathological characteristics of many MAS-affected tissues, particularly pituitary, testicular, and adrenal disease. Other rarer disease related features are emerging. The objective of the investigation was to study the pathological and genetic findings of MAS on a tissue-by-tissue basis in classically and nonclassically affected tissues. This was a comprehensive autopsy and genetic analysis. The study was conducted at a tertiary referral university hospital. An adult male patient with MAS and severe disease burden including gigantism was the subject of the study. Interventions included clinical, hormonal, and radiographic studies and gross and microscopic pathology analyses, conventional PCR, and droplet digital PCR analyses of affected and nonaffected tissues. Pathological findings and the presence of GNAS1 mutations were measured. The patient was diagnosed with MAS syndrome at 6 years of age based on the association of café-au-lait spots and radiological signs of polyostotic fibrous dysplasia. Gigantism developed and hyperprolactinemia, hypogonadotropic hypogonadism, and hyperparathyroidism were diagnosed throughout the adult period. The patient died at the age of 39 years from a pulmonary embolism. A detailed study revealed mosaiscism for the p.R201C GNAS1 mutation distributed across many endocrine and nonendocrine tissues. These genetically implicated tissues included rare or previously undescribed disease associations including primary hyperparathyroidism and hyperplasia of the thymus and endocrine pancreas. This comprehensive pathological study of a single patient highlights the complex clinical profile of MAS and illustrates important advances in understanding the characteristics of somatic GNAS1-related pathology across a wide range of affected organs.